Search This Blog

Wednesday, September 21, 2022

Clovis Oncology, Isotopia Announce Clinical Supply Agreement

 Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopia’s lutetium-177 (177Lu) n.c.a. for use in the clinical development of FAP-2286, Clovis’ fibroblast activation protein (FAP)-targeting therapeutic candidate. FAP-2286 is the first peptide-targeted radionuclide therapeutic (PTRT) candidate directed against fibroblast activation protein undergoing clinical testing and is currently being investigated in the Phase 1/2 LuMIERE study for patients with advanced solid tumors. The agreement covers an initial period of two years. Further details of the agreement were not disclosed.

https://finance.yahoo.com/news/clovis-oncology-isotopia-announce-lutetium-120000928.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.